Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | LIG1 | P18858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1254741 | 0.86 | TLR7 (0.51) | HASPINTLR7GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1829942 | 0.83 | HASPIN (0.44) | HASPINTLR7SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7480837 | 0.82 | TLR7 (0.43) | HASPINTLR7SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1760875 | 0.79 | KMT2A (0.46) | HASPINTLR7MAPTALDH1A1MAPK1 | |
| SCHEMBL7181702 | 0.79 | PGK1 (0.36) | TLR7GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL26640974 | 0.78 | TLR7 (0.39) | HASPINTLR7MAPTALDH1A1 | |
| SCHEMBL21274047 | 0.78 | HASPIN (0.40) | HASPINGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11780377 | 0.77 | MAPT (0.36) | TLR7SMN1; SMN2MAPTALDH1A1MAPK1 | |
| SCHEMBL16019753 | 0.77 | TLR7 (0.47) | HASPINTLR7MAPTALDH1A1MAPK1 | |
| SCHEMBL29121458 | 0.76 | PTGER4 (0.34) | TLR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | Université de Liège (BE) | 2025-06-03 | — | — | US | disclosed |
| CN-113329753-B | Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling | 列日大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-3955929-B1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | UNIV LIEGE (BE) | 2024-05-15 | — | — | EP | disclosed |
| CN-117736210-A | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-114805341-B | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111386271-B | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2023-05-30 | — | — | CN | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | Université de Liège (BE) | 2022-09-06 | — | — | US | disclosed |
| CN-114805341-A | Aromatic heterocyclic compounds and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2020212553-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2020-10-22 | — | — | WO | disclosed |
| CN-111386271-A | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019158655-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIVERSITE DE LIEGE (BE) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019158655-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIVERSITE DE LIEGE (BE) | 2019-08-22 | — | — | WO | disclosed |
| US-9056838-B2 | Intermediates and processes for preparing Ticagrelor | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-06-16 | — | — | US | disclosed |
| US-9056838-B2 | Intermediates and processes for preparing Ticagrelor | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-06-16 | — | — | US | disclosed |
| US-8148385-B2 | Substituted [1,2,3] triazolo[4,5-d]pyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148385-B2 | Substituted [1,2,3] triazolo[4,5-d]pyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | PIGS, TYMP, TYMS | HASPIN 2047/4885TLR7 1334/4885GRIN2D 622/4885 |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | TYMP, TYMS, UMPS | HASPIN 2336/4885TLR7 1835/4885GRIN2D 1606/4885 |
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | P2RY12, P2RY1, P2RY2 | HASPIN 1119/4885TLR7 448/4885GRIN2D 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.